Bone drug tested for myeloma patients too sick for standard care
NCT ID NCT02833610
Summary
This study tested whether the drug denosumab is safe and effective for protecting bones in people with multiple myeloma who also have severe kidney damage. It involved 55 participants who could not take standard bone-protecting drugs due to their kidney condition. Researchers measured changes in bone health markers and side effects over time to see if this approved cancer drug could help this specific group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
Mass General/North Shore Cancer Center
Danvers, Massachusetts, 01923, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02114, United States
-
Newton Wellesley Hospital
Newton, Massachusetts, 02462, United States
-
University Hospitals of Cleveland
Cleveland, Ohio, 44106, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.